This study is in progress, not accepting new patients
Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (Geometry Mono-1)
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at Orange, California and other locations
- Dates
- start:end: about
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Novartis Pharmaceuticals
- Links
- For interim results on this study, please click the link below to the NovartisClinicalTrial.com website
- ID
- NCT02414139
- Phase
- Phase 2 research study
- Study Type
- Interventional
- Participants
- About 373 people participating
- Last Updated